Latest News and Press Releases

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...

Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and NASDAQ First North Growth Market in Iceland under the symbol “ALVO” ...

Four new members enhance independence and diversity of Board of Directors Alvotech (NASDAQ and First North Growth Market: ALVO), a global biotech company specialized in the development and...

Fjölbreyttari samsetning stjórnar með aðkomu óháðra stjórnarmanna Alvotech (NASDAQ og First North Growth „ALVO“) tilkynnti í dag um fjölgun í stjórn fyrirtækisins, í tengslum við skráningu...

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studiesEylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion...

AVT06 er þriðja líftæknilyfjahliðstæða Alvotech sem tekin er til klínískrar rannsóknarGert er ráð fyrir að um 444 sjúklingar taki þátt í rannsókninni Eylea® (aflibercept) er lyf við augnsjúkdómum en...

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10...

The board of directors of Alvotech (the “Company”) has resolved to increase the Company´s share capital by an amount of two hundred seventy thousand seven hundred twenty-one US dollars and sixty-seven...

After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to list its shares under the ticker symbol “ALVO” on the Nasdaq First North Growth Market in Iceland...

In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC),  Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June...